Blank, M., Mandel, M., Dror, N., Solomon, A., Barlyia, T., & Lavie, D. (2017). Hypericin targets multiple signaling mediators in cancer cells generating unique, diverse anti-tumoral, anti-metastatic, and anti-angiogenic activities with evidence for clinical applicability. Medical Research Archives, 5(3). Retrieved from https://esmed.org/MRA/mra/article/view/881